General Information

We are a medical technology company that uses our proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, which we refer to as customized, to fit each patient’s unique anatomy. The worldwide market for joint replacement products is approximately $15 billion annually and growing, and we believe our iFit technology platform is applicable to all major joints in this market. We believe we are the only company offering a broad line of customized knee implants designed to restore the natural shape of a patient’s knee. We have sold a total of more than 30,000 knee implants in the United States and Europe. In recent clinical studies, iTotal CR, our cruciate-retaining total knee replacement implant and best-selling product, demonstrated superior clinical outcomes, including better function and greater patient satisfaction compared to off-the-shelf implants. We recently initiated the limited launch of iTotal PS, our posterior-stabilized total knee replacement implant which addresses the largest segment of the knee replacement market. We expect to submit an application for clearance of iTotal Hip, our first customized hip replacement implant, with the U.S. Food and Drug Administration, or FDA, in 2015.

Employees: 353
Founded: 2004
Contact Information
Address 28 Crosby Drive, Bedford, MA 01730, US
Phone Number (781) 345-9001
Web Address
View Prospectus: ConforMIS
Financial Information
Market Cap $586.4mil
Revenues $52.1 mil (last 12 months)
Net Income $-47.3 mil (last 12 months)
IPO Profile
Symbol CFMS
Exchange NASDAQ
Shares (millions): 9.0
Price range $15.00 - $15.00
Est. $ Volume $135.0 mil
Manager / Joint Managers J.P. Morgan/ Deutsche Bank Securities
CO-Managers Wells Fargo Securities/ Canaccord Genuity/ Oppenheimer & Co.
Expected To Trade: 7/1/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change